Generation of monoclonal antibodies specific for mouse apolipoprotein B- 100 in apolipoprotein B-48-only mice

Journal of Lipid Research

Volumn 40, Issue 1, 1999, Pages 76-84

  Zlot, Constance H ^a   Flynn, Laura M ^a   Véniant, Murielle M ^a,b   Kim, Edward ^a,b,c   Raabe, Martin ^a,b   McCormick, Sally P A ^e   Ambroziak, Patricia ^a   McEvoy, Leslie M ^d   Young, Stephen G ^a,b,c  

^a GLADSTONE INSTITUTE OF CARDIOVASCULAR DISEASE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d MERCK RESEARCH LABORATORIES   (United States)

^e UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

Cholesterol; Lipoproteins; Radioimmunoassay; Transgenic mice

Indexed keywords

APOLIPOPROTEIN B100; APOLIPOPROTEIN B48; CHOLESTEROL; LIPOPROTEIN; MONOCLONAL ANTIBODY;

ANIMAL CELL; ANTIBODY PRODUCTION; ANTIBODY TITER; ARTICLE; ATHEROGENESIS; CHOLESTEROL METABOLISM; GENE TARGETING; HYBRIDOMA; IMMUNE RESPONSE; LIPOPROTEIN METABOLISM; MYELOMA CELL; NONHUMAN; PRIORITY JOURNAL; RADIOIMMUNOASSAY; SPLEEN LYMPHOCYTE; TRANSGENIC MOUSE;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY SPECIFICITY; APOLIPOPROTEIN B-100; APOLIPOPROTEIN B-48; APOLIPOPROTEINS B; GENE TARGETING; HUMANS; HYBRIDOMAS; IMMUNOASSAY; MICE; MICE, KNOCKOUT;

EID: 0032894472     PISSN: 00222275     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Young, S. G., S. J. Bertics, T. M. Scott, B. W. Dubois, L. K. Curtiss, and J. L. Witztum. 1986. Parallel expression of the MB19 genetic polymorphism in apoprotein B-100 and apoprotein B-48. Evidence that both apoproteins are products of the same gene. J. Biol. Chem. 261: 2995-2998.
2. Marcel, Y. L., M. Hogue, R. Theolis, Jr., and R. W. Milne. 1982. Mapping of antigenic determinants of human apolipoprotein B using monoclonal antibodies against low density lipoproteins. J. Biol. Chem. 257: 13165-13168.
3. Milne, R. W., R. Theolis, Jr., R. B. Verdery, and Y. L. Marcel. 1983. Characterization of monoclonal antibodies against human low density lipoprotein. Arteriosclerosis. 3: 23-30.
4. Marcel, Y. L., P. K. Weech, P. Milthorp, F. Terce, C. Vezina, and R. W. Milne. 1985. Monoclonal antibodies and the characterization of apolipoprotein structure and function. Prog. Lipid Res. 23: 169-195.
5. Milne, R., R. Théolis, Jr., R. Maurice, R. J. Pease, P. K. Weech, E. Rassart, J-C. Fruchart, J. Scott, and Y. L. Marcel. 1989. The use of monoclonal antibodies to localize the low density lipoprotein receptor-binding domain of apolipoprotein B. J. Biol. Chem. 264: 19754-19760.
6. Young, S. G., R. K. Koduri, R. K. Austin, D. J. Bonnet, R. S. Smith, and L. K. Curtiss. 1994. Definition of a nonlinear conformational epitope for the apolipopiotein B-100-specific monoclonal antibody, MB47. J. Lipid Res. 35: 399-407.
7. Young, S. G., S. J. Bertics, L. K. Curtiss, and J. L. Witztum. 1987. Characterization of an abnormal species of apolipoprotein B, apolipoprotein B-37, associated with familial hypobetalipoproteinemia. J. Clin. Invest. 79: 1831-1841.
8. Weisgraber, K. H., T. L., Innerarity, Y. M. Newhouse, S. G. Young, K. S. Arnold, R. M. Krauss, G. L. Vega, S. M. Grundy, and R. W. Mahley. 1988. Familial defective apolipoprotein B-100: enhanced binding of monoclonal antibody MR47 to abnormal low density lipoproteins. Proc. Natl. Acad. Sci. USA. 85: 9758-9762.
9. Young, S. G., S. T. Hubl, D. A. Chappell, R. S. Smith, F. Claiborne, S. M. Snyder, and J. F. Terdiman. 1989. Familial hypobetalipoproteinemia associated with a mutant species of apolipoprotein B (B46). N. Engl. J. Med. 320: 1604-1610.
10. Welty, F. K., S. T. Hubl, V. R. Pierotti, and S. G. Young. 1991. A truncated species of apolipoprotein B (B67) in a kindred with familial hypobetalipoproteinemia. J. Clin. Invest. 87: 1748-1754.
11. Palinski, W., M. E. Rosenfeld, S. Ylā-Herttuala, G. C. Gurtner, S. S. Socher, S. W. Butler, S. Parthasarathy, T. E. Carew, D. Steinberg, and J. L. Witztum. 1989. Low density lipoprotein undergoes oxidative modification in vivo. Proc. Natl. Acad. Sci. USA. 86: 1372-1376.
12. Ylā-Herttuala, S., W. Palinski, M. E. Rosenfeld, S. Parthasarathy, T. E. Carew, S. Butler, J. L. Witztum, and D. Steinberg. 1989. Evidence for the presence of oxidatively modified low density lipoprotein in atherosclerotic lesions of rabbit and man. J. Clin. Invest. 84: 1086-1095.
13. Young, S. G., R. S. Smith, D. M. Hogle, L. K. Curtiss, and J. L. Witztum. 1986. Two new monoclonal antibody-based enzyme-linked assays of apolipoprotein B. Clin. Chem. 32: 1484-1490.
14. Tsao, B. P., L. K. Curtiss, and T. S. Edgington. 1982. Immunochemical heterogeneity of human plasma apolipoprotein B. II. Expression of apolipoprotein B epitopes on native lipoproteins. J. Biol. Chem. 257: 15222-15228.
15. Curtiss, L. K., and T. S. Edgington. 1982. Immunochemical heterogeneity of human plasma apolipoprotein B. I. Apolipoprotein B binding of mouse hybridoma antibodies. J. Biol Chem. 257: 15213-15221.
16. Tikkanen, M. J., R. Dargar, B. Pfleger, B. Gonen, J. M. Davie, and G. Schonfeld. 1982. Antigenic mapping of human low density lipoprotein with monoclonal antibodies. J. Lipid Res. 23: 1032-1038.
17. Young, S. G., J. L. Witztum, D. C. Casal, L. K. Curtiss, and S. Bernstein. 1986. Conservation of the low density lipoprotein receptor-binding domain of apoprotein B. Demonstration by a new monoclonal antibody, MB47. Arteriosclerosis. 6: 178-188.
18. Haberland, M. E., D. Fong, and L. Cheng. 1988. Malondialdehyde-altered protein occurs in atheroma of Watanabe heritable hyperlipidemic rabbits. Science. 241: 215-218.
19. Farese, R. V., Jr., S. L. Ruland, L. M. Flynn, R. P. Stokowski, and S. G. Young. 1995. Knockout of the mouse apolipoprotein B gene results in embryonic lethality in homozygotes and protection against diet-induced hypercholesterolemia in heterozygotes. Proc. Natl. Acad. Sci. USA. 92: 1774-1778.
20. Huang, L-S., E. Voyiaziakis, D. F. Markenson, K. A. Sokol, T. Hayek, and J. L. Breslow. 1995. ApoB gene knockout in mice results in embryonic lethality in homozygotes and neural tube defects, male infertility, and reduced HDL cholesterol ester and apoA-I transport rates in heterozygotes. J. Clin. Invest. 96: 2152-2161.
21. Véniant, M. M., V. Pierotti, D. Newland, C. M. Cham, D. A. Sanan, R. I., Walzem, and S. G. Young. 1997. Susceptibility to atherosclerosis in mice expressing exclusively apolipoprotein B-48 or apolipoprotein B-100. J. Clin. Invest. 100: 180-188.
22. Farese, R. V., Jr., M. M. Véniant, C. M. Cham, L. M. Flynn, V. Pierotti, J. F. Loring, M. Traber, S. Ruland, R. S. Stokowski, D. Huszar, and S. G. Young. 1996. Phenotypic analysis of mice expressing exclusively apolipoprotein B-48 or apolipoprotein B-100. Proc. Natl. Acad. Sci. USA. 93: 6393-6398.
23. Havel, R. J., H. A. Eder, and J. H. Bragdon. 1955. The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J. Clin. Invest. 34: 1345-1353.
24. McCormick, S. P. A., J. K. Ng, M. Véniant, J. Borén, V. Pierotti, L. M. Flynn, D. S. Grass, A. Connolly, and S. G. Young. 1996. Transgenic mice that overexpress mouse apolipoprotein B. Evidence that the DNA sequences controlling intestinal expression of the apolipoprotein B gene are distant from the structural gene. J. Biol. Chem. 271: 11963-11970.
25. Young, S. G., C. M. Cham, R. E. Pitas, B. J. Burri, A. Connolly, L. Flynn, A. S. Pappu, J. S. Wong, R. L. Hamilton, and R. V. Farese, Jr. 1995. A genetic model for absent chylomicron formation: mice producing apolipoprotein B in the liver, but not in the intestine. J. Clin. Invest. 96: 2932-2946.
26. Harlow, E., and D. Lane. 1988. Antibodies. A Laboratory Manual. Cold Spring Harbor, NY.
27. Kim, E., C. M. Cham, M. M. Véniant, P. Ambroziak, and S. G. Young. 1998. Dual mechanisms for the low plasma levels of truncated apolipoprotein B proteins in familial hypobetalipoproteinemia. Analysis of a new mouse model with a nonsense mutation in the Apob gene. J. Clin. Invest. 101: 1468-1477.
28. Piedrahita, J. A., S. H. Zhang, J. R. Hagaman, P. M. Oliver, and N. Maeda. 1992. Generation of mice carrying a mutant apolipoprotein E gene inactivated by gene targeting in embryonic stem cells. Proc. Natl. Acad. Sci. USA. 89: 4471-4475.
29. Ishibashi, S., M. S. Brown, J. L. Goldstein, R. D. Gerard, R. E. Hammer, and J. Herz. 1993. Hypercholesterolemia in low density lipoprotein receptor knockout mice and its reversal by adenovirus-mediated gene delivery. J. Clin. Invest. 92: 883-893.
30. Linton, M. F., R. V. Farese, Jr., G. Chiesa, D. S. Grass, P. Chin, R. E. Hammer, H. H. Hobbs, and S. G. Young. 1993. Transgenic mice expressing high plasma concentrations of human apolipoprotein B-100 and lipoprotein[a]. J. Clin. Invest. 92: 3029-3037.
31. Young, S. G., S. J. Bertics, L. K. Curtiss, D. C. Casal, and J. L. Witztum. 1986. Monoclonal antibody MB19 detects genetic polymorphism in human apolipoprotein B. Proc. Natl. Acad. Sci. USA. 83: 1101-1105.
32. 2 in subjects with coronary artery disease and hypercholesterolemia. Arteriosclerosis. 7: 61-65.
33. Young, S. G., S. J. Bertics, L. K. Curtiss, B. W. Dubois, and J. L. Witzturn. 1987. Genetic analysis of a kindred with familial hypobetalipoproteinemia. Evidence for two separate gene defects: One associated with an abnormal apolipoprotein B species, apolipoprotein B-37; and a second associated with low plasma concentrations of apolipoprotein B-100. J. Clin. Invest. 79: 1842-1851.
34. Egusa, G., D. W. Brady, S. M. Grundy, and B. V. Howard. 1983. Isopropanol precipitation method for the determination of apolipoprotein B specific activity and plasma concentrations during metabolic studies of very low density lipoprotein and low density lipoprotein apolipoprotein B. J. Lipid Res. 24: 1261-1267.
35. Plump, A. S., J. D. Smith, T. Hayek, K. Aalto-Setälä, A. Walsh, J. G. Verstuyft, E. M. Rubin, and J. L. Breslow. 1992. Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice created by homologous recombination in ES cells. Cell. 71: 343-353.
36. Rigotti, A., B. L. Trigatti, M. Penman, H. Rayburn, J. Herz, and M. Krieger. 1997. A targeted mutation in the murine gene encoding the high density lipoprotein (HDL.) receptor scavenger receptor class B type I reveals its key role in HDL metabolism. Proc. Natl. Acad. Sci. USA. 94: 12610-12615.
37. Declerck, P. J., P. Carmeliet, M. Verstreken, F. De Cock, and D. Collen. 1995. Generation of monoclonal antibodies against autologous proteins in gene-inactivated mice. J. Biol. Chem. 270: 8397-8400.
38. Meydani, S. N., and R. P. Tenerdy. 1993. Vitamin E and Immune Response. In Vitamin E in Health and Disease. L. Packer, and J. Fuchs, editors. Marcel Dekker, New York, 549-561.
39. Nielsen, L. B., S. P. A. McCormick, V. Pierotti, C. Tam, M. D. Gunn, H. Shizuya, and S. G. Young. 1997. Human apolipoprotein B transgenic mice generated with 207- and 145-kilobase pair bacterial artificial chromosomes. Evidence that a distant 5′-element confers appropriate transgene expression in the intestine. J. Biol. Chem. 272: 29752-29758.
40. 48. Curr. Opin. Lipidol. 5: 94-101.
41. Zhang, S. H., R. L. Reddick, J. A. Piedrahita, and N. Maeda. 1992. Spontaneous hypercholesterolemia and arterial lesions in mice lacking apolipoprotein E. Science. 258: 468-471.
42. Nakashima, Y., A. S. Plump, E. W. Raines, J. L. Breslow, and R. Ross. 1994. ApoE-deficient mice develop lesions of all phases of atherosclerosis throughout the arterial tree. Arterioscler. Thromb. 14: 133-140.
43. Véniant, M. M., Zlot, C. H., Walzem, R. L., Pierotti, V., Driscoll, R., Dichek, D., Herz, J., and S. G. Young. 1998. Lipoprotein clearance mechanisms in LDL receptor-deficient "apo-B48-only" and "apo-B100-only" mice. J. Clin. Invest. 102: 1559-1568.